



(RETRANS) ChemoTech's Animal Care Announces First U.S. Order from Leading Equine Clinic in Kentucky

Retransmission of the press release that was published, with the associated MAR label, on December 4th, 2025 at 19:12

Kentucky - US, VQ Animal Care Inc, the U.S. subsidiary of Scandinavian ChemoTech, today announced the receipt of its first U.S. order from an internationally renowned equine clinic in Kentucky at the heart of America's equine industry with operations across multiple locations in US. This agreement marks VQ Animal Care's first commercial collaboration with an equine clinic in the United States, underscoring the company's expanding global footprint in advanced veterinary oncology solutions.

The agreement begins as a rental program, providing the clinic with immediate access to the innovative Tumor-Specific Electroporation (TSE) technology. The program is structured to transition through a lease-to-buy arrangement to a purchase in 2026, ensuring long-term access to cutting-edge treatment capabilities for equine patients. Training and installation are scheduled to be completed before the end of 2025, enabling the clinic's veterinary teams to begin integrating TSE technology into their oncology services shortly thereafter.

*"We are very pleased to see the strong reputation we have built within equine hospitals and universities across Europe now extending into the U.S. market," said **Stefan Mohan Frick**, CEO of ChemoTech. "This collaboration with one of Kentucky's most respected equine clinics is an important validation of our technology and our mission. We look forward to supporting their team as their experience with TSE grows and are optimistic that this partnership will expand to their other clinics in the future."*

Unique Strengths of TSE in Equine Oncology

VQ Animal Care's Tumor-Specific Electroporation (TSE) technology provides several important advantages for treating equine tumors and sarcoids:

- Often performed **without general anesthesia**, reducing risk and improving safety.
- Tissue-sparing and **minimally destructive**, resulting in less scarring and better cosmetic and functional outcomes.
- **Lower stress for horses** thanks to shorter, less invasive procedures and fast recovery.
- More cost-efficient for owners, with fewer resources needed and lower overall treatment costs.
- **Accessible in a wide range of clinical settings**, as many treatments can be performed with the horse standing under light sedation.

These strengths have made TSE a preferred option in leading European equine hospitals, and its introduction to top U.S. clinics marks an important step in advancing humane and cost-effective cancer care for horses.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.